ResAppDX is a point-of-care diagnostic phone application. It is compatible with both IOS and Android. It diagnoses lower respiratory tract infections by listening to cough sounds.
After an intensive pilot evaluation of the ResAppDx that we undertook at five partner clinics, we are elated to announce the signing of an agreement with ResApp Health, to distribute the diagnostic application in Kenya.
In the partnership with ResApp Health, we will, for an initial term of three years, sell and distribute the ResAppDX throughout our fast-growing market.
How ResAppDX works
ResAppDX is a point-of-care diagnostic phone application. It is compatible with both IOS and Android. It diagnoses lower respiratory tract infections by listening to cough sounds. This acute respiratory diagnostic test analyses the cough signatures it picks through a smartphone’s in-built microphone.
Patients cough and the application’s in-built technology detects lower tract infections. This provides accurate diagnostics which enable evidence-backed treatment.
Coughs and breathing sounds tell vital information about the condition of the respiratory tract. It is based on this that ResApp diagnoses and measures the severity of the following:
- Bronchiolitis, and
- Chronic obstructive pulmonary disease (COPD)
Doctors use stethoscopes to examine respiratory conditions, by listening to the activities of the lungs. While this has been of great help in making a diagnosis, ResApp comes in to improve accuracy and erase the need for human interpretation of respiratory sounds. Here is how:
Stethoscopes hear sounds that are compromised since the sound has to first pass through the chest musculature. This muffles high-pitched components of respiratory sounds. During a bout of coughs, however, the lungs are directly connected to the atmosphere. That is the opportunity that ResApp taps into through automated technology. The device picks audible respiratory sounds that carry crucial information about the respiratory tract condition.
Rolling out of ResAppDX
We are eager to commence the rolling out of ResApp, confident that it is a game-changer. Smartphones installed with ResApp will be provided to facilities that partner with us, and training given on how to effectively use the application.
We shall charge the facilities KES 220/test (VAT included), enabling them to detect respiratory tract infections in their patients and offer apt care and treatment, while increasing their revenue.
The ResApp runs on data bundles, and to facilitate this, we have come up with an arrangement where facilities buy prepaid test-bundles in set packages (similar to how we buy data bundles) on a need basis.
ResAppDx will be available in the market as soon as May 15th this year. We look forward to partnering with you to provide better and accessible health care for all.